CA-JUMPCODE-GENOMICS
13.6.2024 08:01:34 CEST | Business Wire | Press release
Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.
Under the terms of the agreement Jumpcode and Takara Bio USA have each granted the other party a license to use their IP in exchange for an agreed royalty payment. The financial terms were not disclosed. The companies’ combined IP comprises multiple patents and patent applications worldwide, including U.S. Patent 11,708,606, held by Jumpcode, and U.S. Patent 10,150,985, held by Takara Bio USA.
The companies’ cutting-edge technologies, sold under the DepleteX® and CRISPRclean brands by Jumpcode and as ZapR technology by Takara Bio USA, remove unwanted sequences from biological samples to enable the discovery and detection of novel molecules. This enables researchers to significantly improve the sensitivity of their RNA-seq libraries and provides significant cost savings by reducing the need to sequence unwanted abundant sequences.
The technology can be used in multiple research and translational applications and has the potential to be utilized to rapidly detect unknown, previously undetectable pathogens, which is critically important, particularly in the event of a future pandemic.
Commenting on the partnership Mike Salter, President and CEO of Jumpcode, said: “We are delighted to partner with Takara. Our combined technology is instrumental to scientists around the world enabling them to deliver groundbreaking research, and we are excited by its potential to transform the future of molecular biology. We look forward to working with Takara Bio USA as we focus on the global commercialisation of our products.”
Carol Lou, President & CEO of Takara Bio USA, said: “We are very pleased to be working with Jumpcode to bring together the innovative technology platforms and foundational IP of both companies. This agreement brings clarity for both Takara Bio USA’s and Jumpcode’s customers and partners and paves the way for both companies to combine their strengths to better enable genomics research.”
About Jumpcode Genomics
Jumpcode Genomics is changing genomics with technology that enables critical workflows for research and clinical applications to break through existing barriers. Our CRISPR-based technology removes uninformative sequences allowing for the sensitive detection of biologically relevant molecules. Combining this technology and next-generation sequencing, it’s now possible to search for and discover novel signals that were previously undetectable for greater insights and broadening the understanding of human biology. Discover what we can do at www.jumpcodegenomics.com. Follow Jumpcode on LinkedIn and Twitter @JumpcodeG.
About Takara Bio
Takara Bio USA, Inc. is a wholly owned subsidiary of Takara Bio Inc. that manufactured and distributes kits, reagents and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification and automated sample preparation.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612041634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa and Bridge Expand Collaboration, with Plans to Bring Stablecoin-Linked Cards to Over 100 Countries3.3.2026 13:00:00 CET | Press release
Collaboration deepens as Bridge’s stablecoin-linked card program gains global momentum Visa (NYSE:V), a global leader in digital payments, and Bridge, a leading stablecoin infrastructure platform and a Stripe company, today announced an expansion of their global card issuance product that they first unveiled in 2025. Bridge enables businesses and fintech developers to offer stablecoin-backed Visa cards. Now, through Bridge’s partnership with Lead Bank, these card transactions can be settled onchain with Visa. Since launching stablecoin-linked cards, developers using Bridge have rapidly begun offering these Visa cards across the world, enabling consumers to make everyday purchases from stablecoin balances at any of Visa’s 175M+ merchant locations. Bridge-enabled stablecoin-linked cards are now live in 18 countries, with planned expansion to over 100 countries across Europe, Asia Pacific, Africa and the Middle East by end of year. Popular crypto platforms like Phantom and MetaMask are us
AI Is Resetting the Rules of Growth in CPG3.3.2026 13:00:00 CET | Press release
NIQ and Kearney analysis finds challenger brands gaining share as AI reshapes innovation and product discovery NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, produced in collaboration with Kearney, reveals that artificial intelligence is reshaping how consumer packaged goods (CPG) brands innovate and compete—with profound effects on innovation, product discovery, and consumer path to purchase. Over the past three years, established niche brands increased US market share by 1.5 percentage points (2022–2025), while large and mid-size national brands declined by 2.1 percentage points, according to NIQ retail measurement data across all categories. This data signals a structural shift: Scale remains powerful, but scale is no longer destiny. Competitive advantage increasingly depends on agility, precision, and the ability to surface effectively in AI-mediated discovery environments. “We are entering a precision era
TestGorilla Launches New AI Readiness and AI Fluency Assessments to Help Companies Hire for the Skills That Matter Now3.3.2026 11:34:00 CET | Press release
Seven new AI assessments, built on TestGorilla's five-pillar AI Fluency Framework, give hiring teams a science-backed way to evaluate what resumes can no longer reveal. TestGorilla, the skills-based hiring platform trusted by thousands of organisations worldwide, today announced a suite of new assessments and simulation tests purpose-built to help talent acquisition teams evaluate AI readiness and AI fluency off the back of the company’s flagship event: Hire for the AI Era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303398545/en/ Use validated assessments and structured AI video interviews through the TestGorilla platform to measure different aspects of AI fluency across technical and non-technical roles. Inside the platform, tools are clearly labeled with AI fluency making it easy to find and build an assessment. The launch coincides with a crucial shift in the hiring landscape. TestGorilla co-founder and CEO Wouter
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance3.3.2026 11:19:00 CET | Press release
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery. Unlike traditional Extended Depth of Focus lenses, Lucidis® delivers full-range visual performance comparable to a premium trifocal IOL - while preserving contrast sensitivity, visual quality, and minimizing side effects such as halos and glare, hallmarks of its patented fully refractive design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303823337/en/ Swiss Advanced Vision premium IOL lenses for cataract surgery A recent peer-reviewed study, Comparative Analysis of Visual Outcomes Between Lucidis 108M (EDOF) and PhysIOL BVI FineVision (Diffractive) IOLs Using Defocus Curve Measurements by H. Naftali, W. Nasser, and M. Naftali, provides compelling comparative data. The findings show that Lucidis® achieves a d
Türk Telekom and P.I. Works Announce Strategic Collaboration on AI-Driven 5G Network Slicing at MWC Barcelona3.3.2026 10:16:00 CET | Press release
Türk Telekom and P.I. Works today announced a strategic collaboration on AI-driven 5G network slicing assurance, unveiled during GSMA Mobile World Congress (MWC) Barcelona 2026. Türk Telekom has successfully trialed P.I. Works’ AI-powered 5G RAN Slice Assurance solution in Türk Telekom R&D Innovation & Test Center, strengthening its ability to deliver differentiated and performance-assured 5G services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303543772/en/ The solution is designed to ensure network slicing performance by enabling real-time monitoring of slice-level KPIs, early detection of performance degradations, and AI-assisted root cause analysis. With these capabilities, Türk Telekom aims to proactively manage service levels, and ensure consistent service continuity across different 5G slice types. Türk Telekom Ebubekir Şahin stated: “As we approach the 5G era, we continuously evolve our mobile network to deliv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom